Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers

Molecular Cancer Therapeutics

Volumn 10, Issue 3, 2011, Pages 495-504

  Coulthard, Sally A ^a   Redfern, Christopher P F ^a   Vikingsson, Svante ^b   Lindqvist Appell, Malin ^b   Skoglund, Karin ^b   Jakobsen Falk, Ingrid ^b   Hall, Andrew G ^a   Taylor, Gordon A ^a   Hogarth, Linda A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; COMPLEMENTARY DNA; HYPOXANTHINE; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; TETRACYCLINE; TIOGUANINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL STRAIN A549; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; LUNG CANCER; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE DELETION; HUMANS; IMMUNOBLOTTING; NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; PURINES; THIOGUANINE; THIOINOSINE; THIONUCLEOTIDES;

EID: 79955757320     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0798     Document Type: Article

References (37)

1. Yu J, Batova A, Shao L, Carrera CJ, Yu AL. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Clin Cancer Res 1997;3:433-8.
2. Gursky S, Olopade OI, Rowley JD. Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. Cancer Genet Cytogenet 2001;129:93-101.
3. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2003;37:44-57.
4. Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, et al. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res 1999;59:1492-7.
5. Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, Chattopadhyay S, et al. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther 2005;4:1860-6.
6. Chattopadhyay S, Zhao R, Tsai E, Schramm VL, Goldman ID. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol Cancer Ther 2006;5: 2549-55.
7. Savarese TM, Crabtree GW, Parks RE Jr. 5′-Methylthioadenosine phosphorylase-L. Substrate activity of 5′-deoxyadenosine with the enzyme from Sarcoma 180 cells. Biochem Pharmacol 1981;30:189-99.
8. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood 2006;107:898-903.
9. UKALL 2003 (Version 7, August 2009). 2010 [cited]. Available from: http://www.ctsu.ox.ac.uk/projects/leuk/ukall2003.
10. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol 2010;79:1211-20.
11. Lepage GA. Basic Biochemical Effects and Mechanism of Action of 6-Thioguanine. Cancer Res 1963;23:1202-6.
12. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109-11.
13. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-6.
14. Coulthard SA, Hogarth LA, Little M, Matheson EC, Redfern CP, Minto L, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002;62:102-9.
15. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
16. Hogarth LA, Redfern CPF, Teodoridis JM, Hall AG, Anderson H, Case MC, et al. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochem Pharmacol 2008;76:1024-35.
17. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 1996;88:3083-90.
18. van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia 2005;19:1281-4.
19. Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 2009;113:100-7.
20. Coulthard SA, Howell C, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998;92:2856-62.
21. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
22. Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996;56:5653-8.
23. Coulthard S, Redfern C, Vikingsson S, Lindqvist Appell M, Skoglund K, Jakobsen FI, et al. Methods for analysis of methylthioadenosine phosphorylase activity, thiopurine methyltransferase activity and thiopurine metabolites. 2010 [cited]. Available from:http://www.staff.ncl.ac.uk/s.a.coulthard/.
24. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
25. Stet EH, De Abreu RA, Bokkerink JP, Vogels-Mentink TM, Lambooy LH, Trijbels FJ, et al. Reversal of 6-mercaptopurine and 6-methyl-mercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts. Biochem Pharmacol 1993;46:547-50.
26. Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995;55:1670-4.
27. Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, et al. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res 2004;14:373-9.
28. Matheson EC, Hall AG. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis 2003;24:31-8.
29. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 2000;46:507-16.
30. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003;63:100-6.
31. Wang H, Wang Y. LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S(6)-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine. Anal Chem 2010;82:5797-803.
32. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PloS One 2009;4:e5735.
33. Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, Sather HN, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001;97:572-4.
34. Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006;91:881-5.
35. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004;104:2492-8.
36. Yonghao T, Qian H, Chuanyuan L, Yandell DW. Deletions and point mutations of p16, p15 gene in primary tumors and tumor cell lines. Chin Med Sci J 1999;14:200-5.
37. Schramm VL, Gutierrez JA, Cordovano G, Basu I, Guha C, Belbin TJ, et al. Transition state analogues in quorum sensing and SAM recycling. Nucleic Acids Symp Ser (Oxf) 2008;52:75-6.